|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
2.81/-0.50
|
企業價值
5.20M
|
資產負債 |
每股賬面淨值
0.98
|
現金流量 |
現金流量率
--
|
損益表 |
收益
147.81K
|
每股收益
0.06
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/06/01 04:30 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |